高级检索
当前位置: 首页 > 详情页

RETRACTED: The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat (Retracted article. See vol. 719, pg. 128, 2013)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, Wuhan 430074, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Cardiovasc Dis,Dept Hematol, Wuhan 430074, Peoples R China
出处:
ISSN:

关键词: Alendronate Osteopontin Osteoprotegerin Vascular calcification Osteoporosis

摘要:
Vascular calcification is a pathobiological process which leads to high morbidity and mortality in cardiovascular disease. The association between vascular calcification and osteoporosis has been reported widely, and there are close relationships among vascular calcification, related cardiovascular disease and osteoporosis, but the biochemical mechanism of vascular calcification is presently unclear. For exploring the possible mechanism of artery calcification we established aorta calcification in an animal model with vitamin D-3 and warfarin and tested the effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aorta tissue of the rat through measuring gene and protein expression of osteopontin and osteoprotegerin respectively. The results indicated compared with control group, the aortic calcium content of calcification group was obviously increased, osteopontin mRNA and osteoprotegerin mRNA were significantly reduced, and osteoprotegerin and osteopontin protein expressions were reduced. Compared with calcification group, the aortic calcium content of alendronate group was obviously reduced, osteopontin mRNA and osteoprotegerin mRNA were significantly increased, and osteopontin and osteoprotegerin protein expression were increased. We conclude that artery calcification may reduce the expression of osteopontin and osteoprotegerin. Alendronate may inhibit rat aorta calcification by up-regulating osteopontin and osteoprotegerin expression. (C) 2012 Elsevier B.V. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2010]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, Wuhan 430074, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, Wuhan 430074, Peoples R China [*1]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Cardiovasc Dis,Dept Cardiol, 1277 Jiefangdadao, Wuhan 430074, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:1 总访问量:411 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)